Matthias Hillenbrand

Matthias Hillenbrand has over 10 years of experience in the biotechnology and pharmaceutical industries. Matthias has held a variety of roles, including Head of Immunology/Cell Culture and Senior Scientist at Memo Therapeutics AG since 2019, Senior Scientist at Heptares Therapeutics Zürich AG, Schlieren since 2017, Head of Cellular Pharmacology at G7 Therapeutics AG (sold and renamed 2017) since 2015, and Research Scientist at Eberhard Karls Universität Tübingen since 2008. Matthias also participated in the Novartis International Biotechnology Leadership Camp 2012, the EMBO course on the “Structural Characterization of Macromolecular Complexes” at EMBL in 2010, and the BioBusiness - Advanced short program on BioEntrepreneurship at USI Università della Svizzera italiana in 2015. Additionally, they completed community service at Lebenshilfe Germersheim in 2001.

Matthias Hillenbrand began their educational journey in 2002 when they enrolled in the University of Tübingen. During their time there, they earned a Diploma in Biochemistry with a focus on Biochemistry, Immunology, and Organic Chemistry. In 2007, they obtained their Diploma in Biochemistry from the Eberhard Karls Universität Tübingen. Afterward, they joined the MLS PhD program. In 2015, they completed their PhD in Biochemistry from the University of Zurich.